The role of online hemodiafiltration with endogenous reinfusion in the treatment of systemic lupus erythematosus activity resistant to conventional therapy

Mohammed A. Elghiriani, Salah S. Naga, Ibtessam A. Hameed, I. Elgohary, Amal R. Mansour
{"title":"The role of online hemodiafiltration with endogenous reinfusion in the treatment of systemic lupus erythematosus activity resistant to conventional therapy","authors":"Mohammed A. Elghiriani, Salah S. Naga, Ibtessam A. Hameed, I. Elgohary, Amal R. Mansour","doi":"10.3389/fneph.2024.1269852","DOIUrl":null,"url":null,"abstract":"Lupus is a diverse autoimmune disease with autoantibody formation. Lupus nephritis carries a grave prognosis. Complement involvement, namely, C1q deficiency, is linked to activity and renal involvement and could help in their assessment. LN therapies include plasma exchange, immune adsorption, and probably hemodiafiltration with online endogenous reinfusion (HFR), together with traditional immunosuppressive therapies.The aim of this study was to evaluate the role of HFR in improving signs and symptoms of systemic lupus erythematosus (SLE) activity and laboratory parameters in cases not responding to traditional immunosuppressive therapy.A controlled clinical study was conducted on 60 patients with lupus from Group A that was subdivided into two groups: cases 1 (47 patients), those who received traditional medical treatment, and cases 2 (13 patients), those who underwent HFR in addition to medical treatment. Group B consisted of two subgroups: control 1, composed of 20 healthy age- and sex-matched volunteers, and control 2, consisting of 10 cases with different glomerular diseases other than lupus.Serum C1q was determined before and after the HFR as well as induction by medical treatment. Disease activity was assessed using SLEDAI-2K with a responder index of 50; quality of life was assessed using SLEQOL v2, and HFR was performed for the non-responder group.C1q was lower in cases. It can efficiently differentiate between SLE patients and healthy controls with a sensitivity of 81.67% and a specificity of 90%. It can also efficiently differentiate between SLE patients and the control 2 group (non-lupus patients with renal glomerular disease) with a sensitivity of 83.33% and a specificity of 100%. C1q was more consumed in proliferative lupus, and correlated with anti-ds DNA, C3, and C4.C1q efficiently discriminates lupus patients and correlates with proliferative forms. HFR might ameliorate lupus activity and restore C1q.","PeriodicalId":73091,"journal":{"name":"Frontiers in nephrology","volume":" 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/fneph.2024.1269852","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Lupus is a diverse autoimmune disease with autoantibody formation. Lupus nephritis carries a grave prognosis. Complement involvement, namely, C1q deficiency, is linked to activity and renal involvement and could help in their assessment. LN therapies include plasma exchange, immune adsorption, and probably hemodiafiltration with online endogenous reinfusion (HFR), together with traditional immunosuppressive therapies.The aim of this study was to evaluate the role of HFR in improving signs and symptoms of systemic lupus erythematosus (SLE) activity and laboratory parameters in cases not responding to traditional immunosuppressive therapy.A controlled clinical study was conducted on 60 patients with lupus from Group A that was subdivided into two groups: cases 1 (47 patients), those who received traditional medical treatment, and cases 2 (13 patients), those who underwent HFR in addition to medical treatment. Group B consisted of two subgroups: control 1, composed of 20 healthy age- and sex-matched volunteers, and control 2, consisting of 10 cases with different glomerular diseases other than lupus.Serum C1q was determined before and after the HFR as well as induction by medical treatment. Disease activity was assessed using SLEDAI-2K with a responder index of 50; quality of life was assessed using SLEQOL v2, and HFR was performed for the non-responder group.C1q was lower in cases. It can efficiently differentiate between SLE patients and healthy controls with a sensitivity of 81.67% and a specificity of 90%. It can also efficiently differentiate between SLE patients and the control 2 group (non-lupus patients with renal glomerular disease) with a sensitivity of 83.33% and a specificity of 100%. C1q was more consumed in proliferative lupus, and correlated with anti-ds DNA, C3, and C4.C1q efficiently discriminates lupus patients and correlates with proliferative forms. HFR might ameliorate lupus activity and restore C1q.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
内源性再灌注在线血液透析在治疗对常规疗法耐药的系统性红斑狼疮活动中的作用
狼疮是一种可形成自身抗体的多种自身免疫性疾病。狼疮肾炎预后严重。补体受累,即 C1q 缺乏,与活动和肾脏受累有关,有助于对其进行评估。狼疮肾炎疗法包括血浆置换、免疫吸附,可能还有血液滤过和在线内源性再灌注(HFR),以及传统的免疫抑制疗法。这项研究的目的是评估 HFR 在改善对传统免疫抑制疗法无效的系统性红斑狼疮(SLE)活动症状和体征以及实验室指标方面的作用。研究人员对 60 名红斑狼疮患者进行了临床对照研究,并将 A 组细分为两组:1 组(47 名患者)接受传统药物治疗,2 组(13 名患者)在药物治疗的基础上接受 HFR 治疗。B 组包括两个亚组:对照组 1(由 20 名年龄和性别匹配的健康志愿者组成)和对照组 2(由 10 名患有狼疮以外的不同肾小球疾病的病例组成)。采用SLEDAI-2K评估疾病活动性,反应指数为50;采用SLEQOL v2评估生活质量,并对无反应组进行HFR。它能有效区分系统性红斑狼疮患者和健康对照组,灵敏度为 81.67%,特异度为 90%。它还能有效区分系统性红斑狼疮患者和对照 2 组(患有肾小球疾病的非狼疮患者),灵敏度为 83.33%,特异度为 100%。C1q在增殖型狼疮中消耗更多,并与抗ds DNA、C3和C4相关。HFR可改善狼疮活动并恢复C1q。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Vascular injury in glomerulopathies: the role of the endothelium. Editorial: Insights in glomerular disease. The Janus-faced nature of complement in hemodialysis: interplay between complement, inflammation, and bioincompatibility unveiling a self-amplifying loop contributing to organ damage. Comparative iron management in hemodialysis and peritoneal dialysis patients: a systematic review. Analyzing body composition in living kidney donors: impact on post-transplant kidney function.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1